Comparison of Clinical Efficacy and Safety of Metformin Sustained-Release Tablet (II) (Dulening) and Metformin Tablet (Glucophage) in Treatment of Type 2 Diabetes Mellitus

• Published in: Frontiers in endocrinology (Lausanne) 2021-09, Vol.12, p.712200-712200
• Main Authors: Guo, Li-Xin, Liu, Guo-En, Chen, Li, Wang, Hai-Fang, Guo, Jian, Zheng, Xian-Ling, Duan, Bin-Hong, Wang, De-Zhong, Zhu, Wei, Wang, Kun, Tan, Wan-Shou, Chen, Qiu, Li, Quan-Zhong, Yang, Jing, Zhang, Qiu, Xie, Pei-Feng, Lei, Min-Xiang
• Format: Article
• Language: English
• Subjects: Adult; Aged; Blood Glucose - analysis; Delayed-Action Preparations - administration & dosage; Delayed-Action Preparations - adverse effects; diabetes; Diabetes Mellitus, Type 2 - blood; Diabetes Mellitus, Type 2 - drug therapy; Dulening; Endocrinology; Glucophage; Glycated Hemoglobin A - analysis; Humans; Hypoglycemic Agents; Metformin - administration & dosage; Metformin - adverse effects; Metformin - therapeutic use; metformin hydrochloride sustained-release; Middle Aged; Tablets; Treatment Outcome; type 2 diabetes mellitus
• ISSN: 1664-2392; 1664-2392
• DOI: 10.3389/fendo.2021.712200

This study investigated the clinical efficacy and safety of metformin hydrochloride sustained-release (SR) tablet (II) produced by Dulening and the original metformin hydrochloride tablet produced by Glucophage in the treatment of type 2 diabetes mellitus (T2DM). This randomized, open and parallel controlled clinical trial consecutively recruited a total of 886 patients with T2DM in 40 clinical centers between May 2016 and December 2018. These patients were randomly assigned to the Dulening group (n=446), in which patients were treated with Dulening metformin SR tablets, and the Glucophage group (n=440), in which patients were treated with Glucophage metformin tablets, for 16 weeks. The changes in the levels of glycated hemoglobin (HbAc1) and fasting blood glucose (FBG) as well as weight loss were compared between these two groups. Also, the overall incidence of adverse drug reactions (ADRs) and the incidence of ADR of the gastrointestinal system observed in patients of these two groups were also compared. There were no significant differences in demographic and basal clinical characteristics between these two groups. The Dulening and Glucophage groups showed comparable levels of decrease in HbA1c levels, FBG and weight loss after 12-week treatment (all p>0.05). The Dulening group had a significantly lower overall incidence of ADRs as well as gastrointestinal ADR than the Glucophage group. Metformin SR tablets (II) and the original metformin tablets exhibit similar therapeutic efficacy in the treatment of T2DM, but metformin SR tablets (II) has the significantly lower incidence of ADRs than the original metformin tablets.